Moderna Inc. and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer’s potential coronavirus vaccine.
AstraZeneca and the University of Oxford are partnering on the global development and distribution of Oxford’s COVID-19 vaccine.
Pfizer and Germany-based BioNTech, which are collaborating on a messenger RNA vaccine against SARS-CoV-2, plan to start testing in the United States once the Food and Drug Administration gives clearance.
Numerous major global biopharma companies reported first-quarter 2020 earnings. Typically, the COVID-19 pandemic has affected the companies, although not necessarily in a straightforward way. Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted. Here’s a look.
Merck entered a collaboration agreement with the Seattle-based Institute for Systems Biology (ISB) to investigate and define the molecular activity of SARS-CoV-2 infection and the resulting disease, COVID-19.
Gilead Sciences, Kite, and oNKo-innate announced that the companies entered into a three-year cancer immunotherapy research collaboration to support the discovery and development of next-generation drug and engineered cell therapies focused on natural killer (NK) cells.
Waltham, Massachusetts-based TScan Therapeutics entered a collaboration agreement with Novartis to discover and develop novel T-cell Receptor (TCR)-engineered T-cell therapies for solid tumors.
Cambridge, Massachusetts-based Moderna is one of the first companies to move a vaccine against COVID-19 into clinical trials.
Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.
Waltham, Massachusetts-based Arrakis Therapeutics inked a strategic collaboration and license deal with Roche focused on discovering RNA-targeted small molecule (rSM) drugs against a range of targets across all of the Swiss pharma giant’s research and development areas.